Abstract

Nonalcoholic fatty liver disease (NAFLD) covers a spectrum from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis. Free fatty acids (FFA) induce steatosis and lipo-toxicity and correlate with severity of NAFLD. In this study we aimed to investigate the role of exogenous and endogenous ALR (augmenter of liver regeneration) for FFA induced ER (endoplasmatic reticulum) -stress and lipoapoptosis. Primary human hepatocytes or hepatoma cells either treated with recombinant human ALR (rhALR, 15kDa) or expressing short form ALR (sfALR, 15kDa) were incubated with palmitic acid (PA) and analyzed for lipo-toxicity, -apoptosis, activation of ER-stress response pathways, triacylglycerides (TAG), mRNA and protein expression of lipid metabolizing genes. Both, exogenous rhALR and cytosolic sfALR reduced PA induced caspase 3 activity and Bax protein expression and therefore lipotoxicity. Endogenous sfALR but not rhALR treatment lowered TAG levels, diminished activation of ER-stress mediators C-Jun N-terminal kinase (JNK), X-box binding protein-1 (XBP1) and proapoptotic transcription factor C/EBP-homologous protein (CHOP), and reduced death receptor 5 protein expression. Cellular ALR exerts its lipid lowering and anti-apoptotic actions by enhancing FABP1, which binds toxic FFA, increasing mitochondrial β-oxidation by elevating the mitochondrial FFA transporter CPT1α, and decreasing ELOVL6, which delivers toxic FFA metabolites. We found reduced hepatic mRNA levels of ALR in a high fat diet mouse model, and of ALR and FOXA2, a transcription factor inducing ALR expression, in human steatotic as well as NASH liver samples, which may explain increased lipid deposition and reduced β-oxidation in NASH patients. Present study shows that exogenous and endogenous ALR reduce PA induced lipoapoptosis. Furthermore, cytosolic sfALR changes mRNA and protein expression of genes regulating lipid metabolism, reduces ER-stress finally impeding progression of NASH.

Highlights

  • Nonalcoholic fatty liver disease (NAFLD) has emerged as the most common cause of liver disease in the developed countries in both adults and children [1,2,3]

  • Human liver tissues were histologically examined for patients without NAFLD (n = 17), patients with simple liver steatosis (n = 27) and patients with nonalcoholic steatohepatitis (NASH) (n = 29) as described earlier [23] and mRNA expression of ALR, FOXA2 and YWHAZ were analyzed

  • We found a significant reduction of FOXA2 in steatosis (1.98 ± 0.19) and NASH (1.56 ± 0.19) compared to normal liver (2.52 ± 0.22) (Fig 7B), which in part correlates with ALR expression in the same tissue samples (S7C Fig)

Read more

Summary

Introduction

Nonalcoholic fatty liver disease (NAFLD) has emerged as the most common cause of liver disease in the developed countries in both adults and children [1,2,3]. NAFLD encompasses a spectrum of hepatic pathologies, ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC) [1, 4]. Despite the high prevalence of NAFLD and its potential for serious complications, a deeper understanding of the underlying mechanisms that determine the progression to liver damage is necessary to develop effective therapies for NAFLD/ NASH. ALR, augmenter of liver regeneration, (encoded by Gfer [growth factor Erv homolog of Saccharomyces cerevisiae]), a member of the ALR/Erv protein family, was shown to augment the process of liver regeneration, and is denoted as a co-mitogen [6]. ALR was described to have a functional role as a protective and anti-apoptotic cell survival factor [13,14,15,16]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call